Literature DB >> 2476882

High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.

M A Ferro1, D Gillatt, M O Symes, P J Smith.   

Abstract

High-dose intravenous estrogen therapy was shown to be effective in relieving bone pain due to metastatic disease in 22 of 29 (75.9%) men with advanced hormone-resistant prostate cancer. This clinical response was accompanied by significant falls in serum prostate-specific antigen (PSA) levels in 13 (44.8%) patients. It is suggested that this clinical benefit is due to a direct inhibitory effect of estrogen on prostate cancer cells.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2476882     DOI： 10.1016/0090-4295(89)90248-3

Source DB:  PubMed          Journal:  Urology        ISSN： 0090-4295            Impact factor:   2.649


  7 in total

1.  High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate.

Authors:  M Ahmed; S Choksy; C P Chilton; K W Munson; J H Williams
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

2.  The Rab27a-binding protein, JFC1, regulates androgen-dependent secretion of prostate-specific antigen and prostatic-specific acid phosphatase.

Authors:  Jennifer L Johnson; Beverly A Ellis; Deborah Noack; Miguel C Seabra; Sergio D Catz
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

Review 3.  Immunotherapy in prostate cancer: emerging strategies against a formidable foe.

Authors:  Marijo Bilusic; Christopher Heery; Ravi A Madan
Journal:  Vaccine       Date:  2011-07-07       Impact factor: 3.641

4.  Salvage chemotherapy for hormone-refractory prostate cancer: Association of Adriamycin and ifosfamide.

Authors:  Maud Toulmonde; Pascal Démolis; Nadine Houédé
Journal:  Exp Ther Med       Date:  2010-08-26       Impact factor: 2.447

5.  Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time.

Authors:  Philip M Arlen; Fernando Bianco; William L Dahut; Anthony D'Amico; William D Figg; Stephen J Freedland; James L Gulley; Philip W Kantoff; Michael W Kattan; Andrew Lee; Meredith M Regan; Oliver Sartor
Journal:  J Urol       Date:  2008-04-18       Impact factor: 7.450

Review 6.  Hormonal therapy for stage D cancer of the prostate.

Authors:  M R Gudziak; A Y Smith
Journal:  West J Med       Date:  1994-04

7.  Insulin-like growth factor binding protein-6 inhibits prostate cancer cell proliferation: implication for anticancer effect of diethylstilbestrol in hormone refractory prostate cancer.

Authors:  H Koike; K Ito; Y Takezawa; T Oyama; H Yamanaka; K Suzuki
Journal:  Br J Cancer       Date:  2005-04-25       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.